[Skip to Navigation]
Sign In
News From the Food and Drug Administration
May 3, 2022

First Donepezil Transdermal Patch Approved for Alzheimer Disease

JAMA. 2022;327(17):1642. doi:10.1001/jama.2022.6662

The first donepezil transdermal patch for treatment of mild, moderate, or severe Alzheimer disease–related dementia has been approved by the FDA.

Marketed as Adlarity, the donepezil transdermal delivery system is applied weekly to the back, thigh, or buttocks. It is available in 5-mg/d and 10-mg/d strengths, replacing oral donepezil at the same dosages. The system is designed to continuously deliver medication through the skin, maintaining a constant level needed for effective treatment. Transdermal delivery also may reduce the risk of adverse gastrointestinal effects associated with oral donepezil, according to a statement by manufacturer Corium, Inc, as well as ease administration for patients who have trouble swallowing or remembering to take a daily pill.

Add or change institution